Group 1 - The Shanghai Composite Index is at 4005.73 points, above the annual line, with an increase of 0.93% [1] - The total trading volume of A-shares today is 1,402.986 billion yuan [1] - A total of 154 A-shares have surpassed the annual line, with notable stocks showing significant deviation rates including Yingkang Life, Gangtong Medical, and Beilu Pharmaceutical at 10.63%, 10.61%, and 9.97% respectively [1] Group 2 - The top three stocks with the highest deviation rates from the annual line are: - Yingkang Life (12.85% increase, 10.63% deviation) - Gangtong Medical (11.91% increase, 10.61% deviation) - Beilu Pharmaceutical (10.20% increase, 9.97% deviation) [1] - Other notable stocks with significant increases include: - Guanhao Biological (14.87% increase, 8.29% deviation) - Baichu Electronics (6.95% increase, 6.79% deviation) [1] - Stocks with smaller deviation rates that have just crossed the annual line include *ST Yedao, Shiyan Institute, and Shanxi Securities [1]

2025年末，A股上市公司赴港上市热潮持续升温。Wind资讯初步统计显示，截至2025年12月末，包括聚辰股份、天孚通信等在内的超20家A 股上市公司集中披露赴港上市相关公告，或启动筹备工作，或更新进展情况。机构普遍认为，这一趋势推动港股"含A量"持续提升，释放出 内地与香港资本市场协同发力的积极信号，"A+H"双重上市模式有望在2026年延续火热态势。 从市场数据来看，2025年已然成为"A+H"上市的爆发之年。Wind数据显示，全年共有19家A股上市公司成功登陆港股市场，较2024年的3家 同比激增533%；这些公司合计募资约1399.93亿港元，占港股全年新股募资总额的比重超50%，成为港股IPO市场的核心力量。而12月的集 中披露更是将这一热潮推向顶峰，当月披露相关公告的A股公司涵盖半导体、医药健康、智能制造、消费电子等多个重点领域，其中聚辰股 份、天孚通信等科技类企业尤为引人注目。 这一轮赴港上市热潮的背后，是政策支持与市场环境优化的双重驱动。政策层面，内地与香港监管机构持续深化协作，为企业跨境上市铺 路搭桥。证监会此前发布多项资本市场对港合作措施，明确支持内地行业龙头企业赴港上市；香港交易所则在2 ...

公司代码：688192 公司简称：迪哲医药 迪哲（江苏）医药股份有限公司 2026 年第一次临时股东会会议资料 2026 年 1 月 | 2026 | 年第一次临时股东会会议须知 1 | | --- | --- | | 2026 | 年第一次临时股东会会议议程 3 | | 一、 | 关于变更注册资本、修订公司章程并办理工商变更登记的议案 6 | | 二、 | 关于改选公司独立董事及调整董事会专门委员会委员的议案 8 | | 三、 | 关于公司发行 H 股股票并在香港联合交易所有限公司上市的议案 11 | | 四、 | 关于公司发行 股股票并在香港联合交易所有限公司上市方案的议案 12 H | | 五、 | 关于本次 H 股股票发行并上市募集资金使用计划的议案 15 | | 六、 | 关于本次 股股票发行并上市决议有效期的议案 16 H | | 七、 | 关于提请股东会授权董事会及其授权人士全权处理与本次 H 股股票发 | | | 行并上市有关事项的议案 17 | | 八、 | 关于就本次 股股票发行并上市修订《公司章程（草案）》及相关议 H | | | 事规则（草案）的议案 24 | | 九、 | 关于确定公 ...

"江苏军团"规模效益双优 "十四五"时期，有着"苏大强"之称的江苏，交出了分量十足的资本市场成绩单：全省新增上市公司257家，其中约九成为科技企业 或科技含量较高的企业；全省上市公司总数达到721家，累计完成首发融资2259.71亿元、再融资3852.79亿元，为企业技术迭 代、产能扩张提供了充足资金"弹药"。 江苏上市公司群体既担负着引领传统行业转型破局的任务，又承载着科技创新和产业创新深度融合的希望。展望"十五五"，当地 将继续鼓励上市公司不断做优做强，为"经济大省挑大梁"提供坚实支撑。 南京青奥中心双子塔 苏州东方之门建筑群 图虫创意/供图 "十四五"时期，江苏上市公司群体实现了从"量的积累"到"质的飞跃"，成为稳定区域经济大盘的重要力量。 截至2025年12月29日，全省境内上市公司家数达721家，数量占全国的1/8，形成了全国规模领先的上市公司集群；总市值攀升 至8.9万亿元，较"十三五"末增长46%，千亿市值龙头企业从7家增至11家，行业引领作用持续凸显。直接融资渠道持续畅通，"十 四五"时期累计完成首发融资2259.71亿元、再融资3852.79亿元，为企业技术迭代、产能扩张提供了充足资金"弹药 ...

"十四五"时期，江苏资本市场以服务实体经济为核心，多点突破实现跨越式发展，交出一份数据亮眼、 成色十足的硬核答卷。 记者从江苏证监局获悉，截至2025年12月29日，江苏上市公司家数达721家，数量占全国上市公司总量 的八分之一。五年来，江苏资本市场直接融资功能持续强化，累计实现首发融资2259.71亿元、再融资 3852.79亿元，融资规模位居全国第四，为实体经济发展注入强劲动能。截至目前，江苏现有上市公司 总市值达8.9万亿元，较"十三五"末增长46%。千亿市值上市公司由"十三五"末的7家增加到11家，资本 市场"江苏板块"的实力持续攀升。 硬科技成色逐步提升 产业根基愈发坚实 依托江苏雄厚的产业基础，江苏证监局全力推动上市公司结构优化升级，让"硬科技"成色在资本市场持 续彰显。 通富微电（002156）子股份有限公司(以下简称"通富微电")的成长轨迹同样印证了资本市场的赋能价 值。记者获悉，借助IPO、再融资等资本市场融资渠道，通富微电累计募集资金约107.56亿元，持续助 力产能建设与经营规模稳步扩大。截至2024年末，公司营收、净利润较2020年末均实现翻倍；客户布局 上，已覆盖国际巨头企业及各细分 ...

Core Insights - Jiangsu's listed companies are pivotal for regional economic development and are leading in the integration of technological and industrial innovation, with a projected total of 722 companies by December 29, 2025, accounting for 1/8 of the national total and a market capitalization of 8.9 trillion yuan, a 46% increase from the end of the 13th Five-Year Plan [2] Group 1: Financial Performance - In the first half of 2025, Jiangsu's listed companies achieved a total revenue of 1.7 trillion yuan, a year-on-year increase of 1.2%, contributing over 1/4 to the provincial GDP [3] - The net profit reached 152.7 billion yuan, with a year-on-year growth of 3.7%, indicating that the average growth rates for revenue and net profit are above the national average [3] - 60% of companies expanded their revenue, with 40% exceeding 1 billion yuan in revenue, and 45 companies reporting revenue growth over 50% [3] Group 2: Technological Advancement - Jiangsu has focused on directing resources towards high-end manufacturing, artificial intelligence, and biomedicine, with 257 new listed companies in the last five years, 90% of which are technology-oriented [3][4] - The province leads the nation with 115 companies listed on the Sci-Tech Innovation Board and 56 on the Beijing Stock Exchange [3] Group 3: Mergers and Acquisitions - During the 14th Five-Year Plan, Jiangsu's capital market saw 1,057 disclosed mergers and acquisitions, with 573 completed, totaling 304.2 billion yuan, accounting for over 1/9 of the national total [5] - The province has established a robust ecosystem for mergers and acquisitions, enhancing the inclusivity and adaptability of regulations [5][6] - Notable acquisitions include Huahai Chengke's acquisition of 70% of Hengsu Huawai for 1.12 billion yuan, significantly boosting production capacity in the semiconductor sector [6] Group 4: Shareholder Returns - Jiangsu's listed companies distributed a total of 394.6 billion yuan in dividends during the 14th Five-Year Plan, a 45.4% increase from the previous period, with a payout ratio rising to 37.8% [7] - The total amount for share buybacks reached 52.3 billion yuan, 2.6 times that of the previous five years, with 70 companies approved for special loans for buybacks [7] Group 5: Regulatory Environment - Jiangsu's regulatory body has enhanced the precision and effectiveness of oversight, resulting in a more orderly market ecosystem, with 27 companies facing administrative penalties during the 14th Five-Year Plan [8] - The establishment of the "Ningfa Ting Ni" Securities Mediation Court has helped recover over 45 million yuan for 649 investors, showcasing a commitment to investor protection [8]

"十四五"时期，有着"苏大强"之称的江苏，交出了分量十足的资本市场成绩单——截至12月29日，全省 上市公司家数达721家，总市值攀升至8.9万亿元；"十四五"时期，全省新增上市公司257家，其中约九 成是科技企业或科技含量较高的企业。"十四五"时期，江苏上市公司累计完成首发融资2259.71亿元、 再融资3852.79亿元，为企业技术迭代、产能扩张提供了充足资金"弹药"，有力支持了江苏经济发展。 江苏上市公司群体既担负着引领传统行业转型破局的任务，又承载着科技创新和产业创新深度融合的希 望。展望"十五五"，江苏将继续鼓励上市公司不断做优做强，为"经济大省挑大梁"提供坚实支撑。 (详细报道见A5版) 江苏聚焦产业优势，围绕"1650"现代产业体系、"51010"战略性新兴产业集群体系等，支持江苏上市公 司结构优化，"硬科技"成色持续提升。截至目前，科创板、北交所江苏上市公司分别达115家、56家， 数量稳居全国首位。其中，代表半导体行业的通富微电（002156）、代表生物医药行业的迪哲医药，借 助资本市场，在业务规模上都实现了跨越式发展。 近5年来，江苏资本市场新增披露并购重组1057起，完成573起，完成金 ...

Group 1 - The A-share pharmaceutical sector has seen active refinancing activities in 2023, with eight companies completing private placements, raising over 8.5 billion yuan in total [1][3] - Among these, Baili Tianheng led with a fundraising amount of 3.731 billion yuan, followed by Dize Pharmaceutical with 1.773 billion yuan, and Lukang Pharmaceutical with 1.187 billion yuan [3] - The fundraising purposes vary significantly among the companies, with Baili Tianheng and Dize Pharmaceutical focusing on innovative drug research and development [5][6] Group 2 - Baili Tianheng plans to use all raised funds for innovative drug R&D, specifically for platforms related to ADC drugs, multi-specific antibodies, and nuclear medicine [5] - Dize Pharmaceutical's projects include new drug development and international standard innovative drug industrialization, marking it as the first unprofitable company to complete refinancing under the "Science and Technology Innovation Board" framework [5] - Other companies like Aibo Medical and Sanyou Medical have different focuses, with Aibo primarily investing in production line construction and Lukang in high-end formulation manufacturing [5][6] Group 3 - Only two of the eight companies reported net profit growth in the first three quarters, with Sanyou Medical showing a significant increase in both revenue and net profit [7] - Baili Tianheng experienced the largest decline in performance, with a revenue drop of 63.52% and a net loss of 4.95 billion yuan, attributed to decreased sales and increased R&D expenses [7][8] - In contrast, Baili Tianheng reported a substantial revenue increase in Q3, driven by successful collaborations and milestone payments [8] Group 4 - Baili Tianheng has also announced plans to issue debt financing tools with a scale of up to 10 billion yuan for various purposes, including R&D and debt repayment [4] - Dize Pharmaceutical is planning to issue H-shares and list on the Hong Kong Stock Exchange [4] - The competitive landscape in the pharmaceutical industry is intensifying, necessitating continuous investment for companies to maintain technological leadership and market position [8]

Core Viewpoint - The A-share pharmaceutical sector has seen active refinancing activities in 2023, with eight companies completing private placements, raising over 8.5 billion yuan in total, indicating a trend towards innovation and strategic investments in the industry [1][3]. Group 1: Fundraising Activities - Eight pharmaceutical stocks have completed private placements this year, raising a total of over 8.5 billion yuan, with Baili Tianheng leading at 3.731 billion yuan [1][3]. - Three companies raised over 1 billion yuan: Baili Tianheng (3.731 billion yuan), Dize Pharmaceutical (1.773 billion yuan), and Lukan Pharmaceutical (1.187 billion yuan) [3]. - The majority of these placements occurred in the first half of the year, with Baili Tianheng's significant placement completed in September [3]. Group 2: Fund Utilization - Baili Tianheng and Dize Pharmaceutical are directing their funds towards innovative drug research and development, with Baili Tianheng focusing entirely on this area [6]. - Dize Pharmaceutical's projects include new drug development and international standard innovative drug industrialization [6]. - Other companies like Aibo Medical and Lukan Pharmaceutical have varied uses for their funds, including production line construction and high-end formulation manufacturing [6][7]. Group 3: Financial Performance - Among the eight companies, only two reported net profit growth in the first three quarters, with Sanyou Medical showing a significant increase in both revenue and profit [8]. - Baili Tianheng experienced the largest decline in performance, with a 63.52% drop in revenue and a net loss of 4.95 billion yuan [8]. - However, Baili Tianheng reported a substantial revenue increase in Q3, attributed to successful collaborations and clinical trial milestones [9]. Group 4: Market Insights - The competitive landscape in the pharmaceutical industry is intensifying, necessitating continuous investment in innovation to maintain market position [9]. - Refinancing is viewed as a necessary strategy for pharmaceutical companies facing high R&D costs and long profit cycles, enabling them to accelerate innovation and commercialization [9].

Core Viewpoint - The A-share pharmaceutical sector has seen active refinancing activities in 2023, with eight companies completing private placements, raising over 8.5 billion yuan in total, indicating a focus on innovation and strategic investments in the industry [1][3]. Group 1: Fundraising Activities - Eight pharmaceutical stocks have completed private placements this year, raising a total of over 8.5 billion yuan, with Baili Tianheng leading at 3.731 billion yuan [1][3]. - Three companies raised over 1 billion yuan: Baili Tianheng (3.731 billion yuan), Dize Pharmaceutical (1.773 billion yuan), and Lukang Pharmaceutical (1.187 billion yuan) [3]. - The majority of these placements occurred in the first half of the year, with Baili Tianheng's significant placement completed in September [3]. Group 2: Fund Utilization - Baili Tianheng and Dize Pharmaceutical are directing their funds towards innovative drug research and development, with Baili Tianheng focusing entirely on this area [6]. - Dize Pharmaceutical's projects include new drug development and international standard innovative drug industrialization [6]. - Other companies like Aibo Medical and Lukang Pharmaceutical have varied uses for their funds, including production line construction and high-end formulation manufacturing [6][7]. Group 3: Financial Performance - Among the eight companies, only two reported net profit growth in the first three quarters, with Sanyou Medical showing a significant increase in both revenue and profit [8]. - Baili Tianheng experienced the largest decline in performance, with a revenue drop of 63.52% and a net loss of 4.95 billion yuan [8]. - However, Baili Tianheng reported a substantial revenue increase in the third quarter, attributed to successful collaborations and clinical trial milestones [9].